TARO PHARMACEUTICAL INDUS (TARO)       30.41  -0.17 (-0.56%)

30.41  -0.17 (-0.56%)

IL0010827181 - Common Stock

News Image
12 days ago - Seeking Alpha

Taro Pharmaceutical GAAP EPS of $0.19 misses by $0.68, revenue of $139.2M misses by $23.92M (NYSE:TARO)

Taro Pharmaceutical press release (NYSE:TARO): Q3 GAAP EPS of $0.19 misses by $0.68.Revenue of $139.2M misses by $23.92M.

News Image
12 days ago - Taro Pharmaceutical Industries Ltd.

Taro Provides Results for December 31, 2022

News Image
17 days ago - Taro Pharmaceutical Industries Ltd.

Taro to Release Third Quarter Results on January 24, 2023

News Image
3 months ago - Taro Pharmaceutical Industries Ltd.

Taro Provides Results for September 30, 2022

News Image
3 months ago - Taro Pharmaceutical Industries Ltd.

Taro to Release Second Quarter Results on October 27, 2022

News Image
6 months ago - Taro Pharmaceutical Industries Ltd.

Taro Provides Results for the Quarter Ended June 30, 2022

News Image
6 months ago - Taro Pharmaceutical Industries Ltd.

Taro to Release First Quarter Results on July 27, 2022

News Image
9 months ago - Taro Pharmaceutical Industries Ltd.

Taro Provides Results for the Year Ended March 31, 2022

News Image
9 months ago - Taro Pharmaceutical Industries Ltd.

Taro to Announce Full Year Results on May 26, 2022

News Image
a year ago - Taro Pharmaceutical Industries Ltd.

Taro Provides Results for December 31, 2021

News Image
a year ago - Taro Pharmaceutical Industries Ltd.

Taro to Announce Third Quarter Results on January 27, 2022

News Image
a year ago - StockNews.com

Down More Than 20% YTD, Grab These 3 Buy-Rated Healthcare Stocks for a 2022 Rebound

The coronavirus pandemic has accelerated innovations and the adoption of advanced technologies in the healthcare sector. Moreover, national healthcare spending in the United States has increased significantly. The healthcare market is growing and shows promising prospects. Healthcare stocks Fresenius Medical (FMS), Encompass Health (EHC), and Taro Pharmaceutical (TARO) have declined more than 20% year-to-date but could rebound in the coming year.

News Image
a year ago - Taro Pharmaceutical Industries Ltd.

Taro Appoints New Chief Financial Officer